fashion -WSS

fashion

author：fashion 2025-09-27 15:20:49 - browse：48

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Sweden knocks USA out of World Cup in penalty kicks

WSS

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Google and Epic fight stronger regulation of AI in health care

Trump used to be more articulate. What could explain the change?

Custom gene therapy hints at new path for rare disease treatments

Google and Epic fight stronger regulation of AI in health care

Google and Epic fight stronger regulation of AI in health care

entertainment

fashion

entertainment

Continuity nursing helped my family in our darkest PICU moments

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

In age of alternative facts, a scholarly course on calling out crap

Trump used to be more articulate. What could explain the change?

Walensky prepares to leave CDC — and Congress — behind

Slovenia has suffered its worst

Continuity nursing helped my family in our darkest PICU moments

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

As demand for Covid shots wanes, Moderna seeks its next success

Why hospitals are withdrawing from US News rankings

hotspot

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Custom gene therapy hints at new path for rare disease treatments

Failure, not just success, should guide future doctors

At Orexo, a ‘turning point’ for everything but digital health

Sage considers ways to reduce costs following FDA rejection

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

entertainment

Wikipedia

hotspot

explore